Search
Physician-scientist Emily Cheng studies the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy.
Computational biologist Dana Pe’er combines single-cell and spatial profiling technologies with machine learning approaches to address fundamental questions in gene regulation, cellular plasticity and cell-cell communication in the contexts of cancer, immunity and development.
Cancer geneticist Kenneth Offit focuses on gene characterization; genetic and epidemiologic studies of cancer-predisposing alleles; and the therapeutic, prognostic, and psychosocial translation of these findings.
Physician-Scientist A. Ari Hakimi, MD studies genetic and metabolic mechanisms of immune response in kidney cancers.
Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.
Cancer biologist Tuomas Tammela investigates cellular heterogeneity in lung and pancreatic cancers.
The Studer laboratory investigates human stem cells as tools to understand normal and pathological development in the nervous system and to develop cell-based strategies for regenerative medicine.
The Baylies laboratory studies the mechanisms that form and maintain muscle both during normal development and in disease.
Molecular biologist Dirk Remus investigates mechanisms of DNA replication in eukaryotic cells.
Physician-scientist Samuel Singer studies the genomic alterations that define new targets for therapy in sarcoma. I am a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma. I have extensive experience with this group of cancers, and am one of just a few surgeons in the world focused solely on treating sarcoma patients. My years of experience have enabled me to devise surgical techniques that improve the ability to completely remove these tumors. In addition to my clinical sarcoma practice, I conduct laboratory research to develop new methods to improve the diagnosis and treatment of sarcoma. I lead both a National Cancer Institute Specialized Program in Research Excellence (SPORE) and the Sarcoma Genome Project.